Investigating how a specific enzyme affects cell death in type 1 diabetes
iPLA2beta-mediated alternative splicing and beta-cell death in type 1 diabetes
This study is looking at how a specific enzyme called iPLA2β might cause the insulin-producing cells in your pancreas to die in type 1 diabetes, and it hopes to find new ways to protect these cells and improve treatment options for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10765734 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the enzyme iPLA2β in the death of insulin-producing beta cells in type 1 diabetes (T1D). By examining how this enzyme contributes to cell death under stress conditions, such as inflammation and high blood sugar, the study aims to identify potential therapeutic targets. The researchers will explore the biochemical pathways involved and how inhibiting iPLA2β may help preserve beta cell function and prevent the progression of T1D. Patients may benefit from new treatment strategies that arise from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes, particularly those experiencing challenges with beta cell function.
Not a fit: Patients with type 2 diabetes or other forms of diabetes unrelated to beta cell apoptosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that help preserve insulin-producing cells and improve outcomes for patients with type 1 diabetes.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for preserving beta cell function in diabetes, indicating potential for success in this approach.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Chalfant, Charles E. — University of Virginia
- Study coordinator: Chalfant, Charles E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.